Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study

Jiafei Xi1*, Honghu Zhu2*, Daqing Liu3*, Xue Nan3*, Wen Zheng3, Kaiyan Liu4*, Wei Shi1, Lin Chen1, Yang Lv1, Fang Yan1, Yanhua Li1, Xiaoyan Xie1, Yunfang Wang1, Wen Yue1, Xin Xu4, Xiaofei Wei4*, Jun Zhu3*, Xiaojun Huang3*, Xuetao Pei1*

1 Stem Cell and Regenerative Medicine Lab, Beijing Institute of Transfusion Medicine, Beijing, China, 2 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China, 3 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, 4 Beijing Cord Blood Bank, Beijing, China

Abstract

Background: Currently, a constant shortage in the supply of platelets has become an important medical and society challenge, especially in developing country, and the in vitro production of megakaryocytic progenitor cells (MPs) from cord blood could represent an effective platelet substitute. In the present study, our objective was to determine the safety and feasibility of ex vivo generated MPs in patients.

Methods and Findings: MPs were produced and characterized from cord blood mononuclear cells under a serum free medium with cytokines. We investigated the feasibility of expansion and infusion of cord blood-derived MPs in 24 patients with advanced hematological malignancies. The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. No adverse effects were observed in patients who received ex vivo-generated cells at concentrations of up to a median value of 5.45 × 10^6 cells/kg of body weight. With one year follow-up, acute and chronic GVHD had not been observed among patients who received MPs infusion, even without ABO blood group and HLA typing matching.

Conclusions: These initial results in patients are very encouraging. They suggest that infusion of cord blood-derived MPs appears safe and feasible for treatment of thrombocytopenia.

Trial Registration: ChiCTR-TCH-09000333.

Introduction

Thrombocytopenia is a common and potentially fatal complication of chemotherapy and hematopoietic stem cell transplantation. Infusion of platelets from unrelated donors is currently the only effective treatment to prevent fatal hemorrhage. However, owing to their short storage time and increased demand, a constant shortage in the supply of platelets has become an important medical and society challenge. [1] Therefore, investigation of alternative sources of platelets would be beneficial.

Hematopoietic stem cells (HSCs) can be used to generate functional megakaryocytic progenitors (MPs), megakaryocytes, and platelets on a large scale. [2,3,4] Functional MPs and platelets have successfully been produced in vitro from CD34+ hematopoietic cells from bone marrow, cord blood, and peripheral blood. [5,6,7] Several studies have reported that transplantation of in vitro auto-producing MPs can promote platelet recovery after high-dose therapy and HSC transplantation. [8,9].

Umbilical cord blood is an abundant source of HSCs. [10,11] Furthermore, cord blood is highly enriched in committed hematopoietic progenitor cells, including those of the megakaryocytic lineage. In vitro large scale production of MPs from cord blood could represent an effective platelet substitute. In vitro cord blood-derived MPs can be used in many non-emergency conditions, allowing platelets to be used for the emergency conditions. However, there are no reports in the literature that document the safety and efficacy of ex vivo-expanded cord blood-derived MPs in clinical trials.

Following high-dose chemotherapy, neutropenia and thrombocytopenia places patients at an increased risk of developing severe...
infectious and bleeding complications. The transplantation of \textit{ex vivo}-generated hematopoietic progenitor cells in addition to chemotherapy represents a possible treatment for high-dose chemotherapy-induced cytopenia. Theoretically, the additional transplantation of \textit{ex vivo} generated progenitor and post-progenitor cells might lead to the production of sufficient numbers of mature functional cells within a few days after transplantation. The feasibility and efficacy of this approach with regard to neutrophil recovery has previously been demonstrated. [12,13] However, potential clinical benefits of transplanted cord blood derived MPs has not yet been shown.

We successfully generated MPs from cord blood using a combination of cytokines. Based on promising results of our preclinical study, state food and drug administration (SFDA) of China approved our group to conducts a clinical trial of MP injection to patients with hematologic malignancy. We report the results of our phase 1 study of cord blood-derived MPs in 24 patients with hematologic malignancy. We believe this to be the first report of MPs from cord blood in a human clinical trial.

**Methods**

**Trial Protocols**

The protocols for this trial are available as supporting information; see Protocol S1 and S2.

**Table 1. Patient characteristics.**

| No | Age | Gender | Diagnosis | Time of Diagnosis | Chemotherapy courses | Last Chemotherapy | Recruitment time | Interval time | Chemotherapy regimen |
|----|-----|--------|-----------|-------------------|----------------------|-------------------|-----------------|--------------|----------------------|
| 1  | 39  | F      | NHL IVA   | 2008-6-26         | 9                    | 2009-4-7          | 2009-4-14       | 8            | GEMOX-ENDOSTAR       |
| 2  | 21  | M      | NHL IVB   | 2008-9-12         | 10                   | 2009-5-5          | 2009-5-19       | 14           | DICE-ENDOSTAR        |
| 3  | 29  | M      | HL IVB    | 1992-6-14         | 10                   | 2009-6-1          | 2009-6-26       | 26           | AraC                 |
| 4  | 56  | M      | NHL IVB   | 2009-2-16         | 7                    | 2009-6-22         | 2009-7-10       | 19           | DICE-ENDOSTAR        |
| 5  | 26  | M      | NHL IVB   | 2009-5-4          | 3                    | 2009-7-8          | 2009-7-21       | 14           | CAT                  |
| 6  | 62  | F      | MM III    | 2009-7-9          | 1                    | 2009-7-19         | 2009-7-30       | 12           | BTD                  |
| 7  | 47  | F      | NHL IVB   | 2009-6-23         | 1                    | 2009-7-30         | 2009-8-7        | 9            | R-CHOP               |
| 8  | 40  | M      | NHL IVB   | 2009-8-11         | 3                    | 2009-8-11         | 2009-8-21       | 11           | MTX                  |
| 9  | 30  | M      | NHL IVA   | 2009-4-17         | 5                    | 2009-8-28         | 2009-9-22       | 26           | VALP                 |
| 10 | 65  | F      | NHL IVB   | 2004-9-16         | 16                   | 2009-9-9          | 2009-10-16      | 37           | FC                   |
| 11 | 19  | F      | NHL IVB   | 2009-7-16         | 5                    | 2009-10-14        | 2009-10-28      | 15           | DICE-ENDOSTAR        |
| 12 | 35  | M      | NHL       | 2009-11-4         | 1                    | 2009-11-4         | 2009-11-12      | 9            | VDLP                 |
| 13 | 27  | M      | NHL IVB   | 2009-10-29        | 1                    | 2009-11-6         | 2009-11-20      | 15           | VDLP                 |
| 14 | 45  | M      | NHL IVA   | 2008-2-26         | 17                   | 2009-11-25        | 2009-12-7       | 14           | AraC+ATO+Tioprinin   |
| 15 | 45  | M      | NHL IVA   | 2008-5-21         | 9                    | 2009-12-13        | 2009-12-15      | 3            | GEMOX                |
| 16 | 31  | F      | NHL IVA   | 2007-12-26        | 16                   | 2009-12-14        | 2009-12-26      | 13           | VDLP                 |
| 17 | 57  | F      | NHL IVB   | 2009-7-1          | 5                    | 2009-12-12        | 2010-1-15       | 33           | RFC                  |
| 18 | 59  | F      | NHL IIIb  | 1992-4-10         | 17                   | 2010-1-14         | 2010-1-26       | 13           | DICE-ENDOSTAR        |
| 19 | 48  | M      | NHL IIIb  | 2009-11-18        | 3                    | 2010-1-25         | 2010-2-9        | 16           | EP                   |
| 20 | 31  | M      | NHL IA    | 2009-12-14        | 4                    | 2010-3-12         | 2010-3-23       | 12           | MTX                  |
| 21 | 50  | F      | NHL IVA   | 2009-8-7          | 6                    | 2010-1-15         | 2010-4-16       | 91           | FC                   |
| 22 | 15  | M      | NHL IVA   | 2010-1-25         | 1                    | 2010-4-10         | 2010-4-21       | 11           | BFM-90               |
| 23 | 32  | M      | NHL IVA   | 2009-10-12        | 6                    | 2010-4-19         | 2010-5-9        | 20           | MTX                  |
| 24 | 45  | M      | NHL IIIb  | 2007-2-1          | 9                    | 2010-3-31         | 2010-5-24       | 54           | R-COP                |

doi:10.1371/journal.pone.0054941.t001
Table 2. Ex vivo expansion: Summary of product characteristics before and after expansion.

| NO. | Before expansion | After expansion | Composition of Transplanted Grafts |
|-----|------------------|-----------------|-----------------------------------|
|     | Volume of CB (ml) | MNC \( \times 10^7 \) | % CD41+ | Expansion time (day) | MNC \( \times 10^7 \) | % CD41+ | Absolute CD41+ (\( \times 10^6 \)) | Cell Viability | Fold expansion | Body Weight | MNC per kg b.w. (\( \times 10^6 \)) | CD41+ cells per kg b.w. (\( \times 10^6 \)) |
| 1   | 78               | 4.5             | 6     | 11 | 58.5 | 52 | 304 | 91.4% | 113 | 70 | 8.4 | 4.3 |
| 2   | 54               | 8               | 11    | 5  | 48  | 26 | 125 | 94.0% | 14  | 61 | 7.9 | 2.0 |
| 3   | 69               | 24              | 4     | 7  | 264 | 33 | 871 | 98.7% | 91  | 67 | 39.4 | 13.0 |
| 4   | 47               | 4.6             | 8     | 6  | 611 | 22 | 1344 | 98.0% | 365 | 57 | 107.2 | 23.6 |
| 5   | 93               | 8.1             | 3     | 8  | 729 | 27 | 197 | 98.9% | 81  | 92 | 7.9 | 2.1 |
| 6   | 82               | 16              | 8     | 7  | 128 | 22 | 282 | 99.0% | 22  | 54 | 23.7 | 5.2 |
| 7   | 106              | 18              | 6     | 4  | 54  | 13 | 70  | 99.9% | 6   | 60 | 9.0 | 1.2 |
| 8   | 52               | 4.6             | 9     | 17 | 874 | 64 | 559 | 97.1% | 135 | 81 | 10.8 | 6.9 |
| 9   | 77               | 1.9             | 13    | 20 | 323 | 55 | 178 | 92.2% | 7   | 67 | 4.8 | 2.7 |
| 10  | 62               | 6               | 6     | 4  | 36  | 9  | 32  | 99.0% | 9   | 57 | 6.3 | 0.6 |
| 11  | 70               | 5               | 12    | 12 | 130 | 72 | 936 | 87.8% | 156 | 79 | 16.5 | 11.8 |
| 12  | 77               | 7               | 5     | 14 | 119 | 67 | 797 | 93.0% | 228 | 67 | 17.8 | 11.9 |
| 13  | 72               | 10              | 6     | 4  | 20  | 8  | 16  | 95.0% | 3   | 63 | 3.2 | 0.3 |
| 14  | 78               | 9               | 9     | 12 | 198 | 77 | 1525 | 91.0% | 188 | 70 | 28.3 | 21.8 |
| 15  | 86               | 10              | 8     | 14 | 310 | 54 | 1674 | 84.4% | 209 | 86 | 36.0 | 19.5 |
| 16  | 99               | 15              | 6     | 7  | 120 | 23 | 276 | 93.7% | 31  | 82 | 14.6 | 3.4 |
| 17  | 56               | 11              | 5     | 4  | 44  | 13 | 57  | 98.0% | 10  | 78 | 5.6 | 0.7 |
| 18  | 93               | 9               | 5     | 8  | 135 | 37 | 500 | 84.0% | 111 | 80 | 16.9 | 6.2 |
| 19  | 89               | 12              | 8     | 13 | 192 | 58 | 1114 | 95.1% | 116 | 66 | 29.1 | 16.9 |
| 20  | 70               | 20              | 5     | 13 | 380 | 63 | 2934 | 92.0% | 293 | 80 | 47.5 | 29.9 |
| 21  | 72               | 6               | 9     | 22 | 96  | 32 | 307 | 94.2% | 57  | 50 | 19.2 | 6.1 |
| 22  | 102              | 29              | 6     | 6  | 132 | 18 | 238 | 93.9% | 14  | 88 | 15.0 | 2.7 |
| 23  | 65               | 6.6             | 11    | 16 | 85  | 52 | 442 | 92.0% | 61  | 78 | 10.9 | 5.7 |
| 24  | 75               | 5.1             | 8     | 11 | 56  | 48 | 269 | 90.2% | 66  | 61 | 9.2 | 4.4 |
|     | Median (range)   | 76 (47–106)     | 8.55  | 7 (1.9–29) | 95 (4–22) | 107.5 (20–611) | 35 (8–77) | 305.5 (16–2934) | 93.95% (84–99.90%) | 73.5 (3–365) | 68.5 (50–92) | 14.8 (3.2–107.2) | 5.45 (0.3–29.9) |

CB, cord blood; MNC: mononuclear cells.
doi:10.1371/journal.pone.0054941.t002
**Table 3. Adverse reaction in MP-infusion patients.**

| Adverse events                  | No | Patient Number |
|--------------------------------|----|----------------|
| Fever                          | 2  | 10, 15         |
| Anaphylaxis                    | 0  | NA             |
| Hemolysis                      | 0  | NA             |
| Shock                          | 0  | NA             |
| Embolism                       | 0  | NA             |
| Hepatolienomegaly              | 0  | NA             |
| Abnormal electrocardiogram     | 0  | NA             |
| Transaminitis                  | 4* | 1, 2, 7, 20    |
| Abnormal renal function        | 0  | NA             |
| Jaundice                       | 1+ | 7              |
| Vomiting                       | 1  | 20             |
| Diarrhea                       | 0  | NA             |
| Erythra                        | 0  | NA             |
| GVHD                           | 0  | NA             |

*All four patients exhibited increased transaminitis before infusion of MPs.
†Jaundice existed before infusion of MPs.

doi:10.1371/journal.pone.0054941.0003

Ethics Statement

The study was approved by Research Ethics Committee of Peking University Cancer Hospital & Institute and by the SFDA of China. All patients provided written informed consent in accordance with the principles of the Declaration of Helsinki before enrollment. We obtained informed written consent from the next of kin, parents or guardians on the behalf of the minors/children participants involved in our study.

Patient Inclusion and Exclusion Criteria

Twenty-four consenting patients with advanced hematological malignancy were enrolled in this study. The target size of our study is 20-30 patients. Patients with hematological malignancy were eligible to receive MPs if they met the following criteria: 12–60 years of age; post-chemotherapy; 20 × 10^9/L PLT; no serious damage to liver and kidney function; written informed consent. The exclusion criteria: thrombocytopenia without cancer chemotherapy; patients with primary disease in important organs; patients who were not accompanied by the immune system disease, serious infections, mental disorders or organ transplant recipients; pregnant, breast-feeding women; patients did not sign informed consent form; infusion contraindication about injection of umbilical cord blood MPs.

Study Design

This was a single-center, open-label, phase 1 clinical trial designed to assess the safety profile of infusion of ex vivo-expanded cord blood-derived MPs after chemotherapy. MPs from cord blood were infused when the platelet of patients was 20 × 10^9/L; no serious damage to liver and kidney function; written informed consent. The interval time between the cord blood MPs preparation and patient infusion was two hours. Before MP infusion, the patients was given 10 ml 10% calcium gluconate to prevent anaphylaxis. The overall infusion time was within two hours. Platelet counts were assessed at least twice per week. After treatment with cord blood-derived MPs, we conducted one-year follow-up. The study flow chart is depicted in Figure 1. This study was registered with http://www.chictr.org, number ChiCTR-TCH-09000333.

In vitro Suspension Culture

After informed consent had been obtained, cord blood from healthy volunteers was collected into sterile heparinized tubes. Mononuclear cells were obtained by centrifugation on Lymphoprep density gradient. Ex vivo cultures were set up with cord blood MNCs at 3 × 10^6 cells/mL in StemSpan medium supplemented with 50 ng/mL thrombopoietin (TPO) (Shenyang Sunshine Pharmaceutical Company Limited), 20 ng/mL interleukin-3 (IL-3) (Peprotech), 50 ng/mL stem cell factor (SCF) (Peprotech) and 50 ng/mL IL-6 (Peprotech) using 75 cm² tissue culture flasks (Corning). At indicated time points, the cultured cells were harvested, washed, and prepared for immediate infusion.

Flow Cytometry Analysis

Ex vivo-generated cells were characterized by flow cytometry on day 0, 7, 10, and 14. All of the conjugated antibodies and the corresponding isotype controls were purchased from BD Pharminogen. The antibodies used were CD3, CD14, CD19, CD41, CD56, and CD61. MPs were collected and washed twice in PBS with 0.1% BSA and stained in accordance with the manufacturer’s suggested concentration of conjugated antibody for 30 min at 4°C. The stained cells were then washed twice in PBS with 0.1% BSA and fixed with the wash buffer supplemented with 1% paraformaldehyde. The samples were then analyzed using a flow cytometer (Becton Dickinson). Cell populations were analyzed with the CellQuest program (Becton Dickinson). Three experiments were performed. We also analyzed the cell size and the co-staining of CD41 on the cultured MPs.

Colony Forming Unit-MK Assay

To demonstrate Colony forming unit-MK colonies, 5 × 10^4 in vitro cultured cells were cultured with MegaCult-C media (StemCell Technologies) in the presence of 10 ng/mL recombinant human IL-3 (Peprotech), 20 ng/mL recombinant human IL-6 (Peprotech), and 50 ng/mL recombinant human TPO (Shenyang Sunshine Pharmaceutical Company Limited) according to the instruction manual. After 10-14 days, the cells were fixed, dried, and stained with an anti-CD41 specific antibody or isotype control antibody according to the manufacturer’s instructions. CFU-MK colonies were defined as colonies with at least 3 megakaryocytes. Three experiments were performed.

Megakaryocytes Analysis

For morphological analysis of mature megakaryocytes in the culture, day 14 cultured cells were centrifuged using a cytopsin centrifuge. Slides were then stained with Wright-Giemsa. We also analyzed the platelets generation in the day 14 culture by flow cytometry. Culture-derived platelets were enumerated as CD41+ events with the same scatter properties as blood platelets. Ten thousand events were counted per sample. Three experiments were performed.

End Points and Definitions

The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. Patients were monitored after the infusion of MPs for infusional toxicity and adverse events, which were evaluated according to World Health Organization (WHO) criteria. Secondary end points included platelet recovery after infusion of MPs. The ABO blood group and HLA typing of patients and paired cord blood were carried out at Department of hematology, Peking University People’s Hospital, (Beijing, China).
Results

Patients and MP Characteristics

Twenty-four patients (nine females/fifteen males) were treated between March 2009 and May 2010. The study flow chart is depicted in Figure 1. The median age was 37 years (range, 15–65 years), and the median weight was 68.5 kg (range, 50–92 kg). The patient group included 22 patients with non-Hodgkin’s lymphoma (NHL), one patient with Hodgkin’s lymphoma (HL), and one patient with multiple myeloma (MM). The median number of previous chemotherapy courses were of five (range, 1–17), and the median interval time between the last chemotherapy and MP infusion was 14 days (range, 3–91 days). Baseline characteristics are presented in Table 1.

Our preclinical studies had established the method to efficiently inducing and expanding cord blood mononuclear cells (MNCs) to MPs. The in vitro producing MPs were characterized by morphological observation, flow cytometry analysis, and colony formation detection. Cell morphology changed obviously with the extension of culture time (Figure S1A). Flow cytometry analysis showed that the expression of CD41 (a MPs marker, Figure S1E) and CD61 (MPs, Figure S1G) was greater at day 14 than day 0 (7.9 fold and 11.6 fold), while the expression of CD3 (T cells, Figure S1B), CD19 (B cells, Figure S1D), CD56 (NK cells, Figure S1F) was lower at day 14 than day 0 (6.7 fold, 95 fold and 17.5 fold). And the expression of CD14 (monocytes, Figure S1C) was also lower at day 14 than day 0 (1.6 fold). Expansion of CFU-Mk were compared in different culture time. Ex vivo expansion achieved a 64±7 fold increase in CFU-MK by 14 days culture (Figure S1H). Morphological features of day 14 cultured cells and the presence of polyploid nuclei were confirmed by microscopy (Figure S1I). This results showed that the ex vivo-generated-MPs can mature to megakaryocytes at day 14 culture. Although, the number of mature megakaryocytes were still low. And we also showed that the MKs in culture produced platelets. The platelets in culture were enumerated by flow cytometry as particles having the same scatter properties as blood platelets and expressing CD41 antigen. The number of platelets released remained relatively low with a mean of 5.5±0.9% of the total expanded population on day 14. Moreover, we analyzed the cell size and co-staining of CD41. And the results of a representative experiment was shown in Figure S2.

Twenty-four umbilical cord blood units identified for MP manufacture contained a median of 8.55×10⁷ MNCs (range, 1.9–29 cells) and a median of 76 mL (range 47–106 mL). The results of ex vivo expansion culture are summarized in Table 2. The median expansion was 73.5-fold (range, 3-365-fold). After expansion culture, the median proportion of CD41+ cells was also lower at day 14 than day 0 (1.6 fold). Expansion of CFU-Mk were compared in different culture time. Ex vivo expansion achieved a 64±7 fold increase in CFU-MK by 14 days culture (Figure S1H). Morphological features of day 14 cultured cells and the presence of polyploid nuclei were confirmed by microscopy (Figure S1I). This results showed that the ex vivo-generated-MPs can mature to megakaryocytes at day 14 culture. Although, the number of mature megakaryocytes were still low. And we also showed that the MKs in culture produced platelets. The platelets in culture were enumerated by flow cytometry as particles having the same scatter properties as blood platelets and expressing CD41 antigen. The number of platelets released remained relatively low with a mean of 5.5±0.9% of the total expanded population on day 14. Moreover, we analyzed the cell size and co-staining of CD41. And the results of a representative experiment was shown in Figure S2.

| Patient No | PLT Day 0×10⁹/L | Platelets (PLT) Days with PLT | Number of PLT transfusions |
|------------|-----------------|-------------------------------|---------------------------|
|            |                 | Less than 20×10⁹/L | More than 60×10⁹/L | More than 100×10⁹/L |
| 1          | 52              | 13               | NA              | NA              | 0                       |
| 2          | 57              | NA               | 4               | 8               | 0                       |
| 3          | 46              | NA               | 2               | 5               | 1                       |
| 4          | 49              | 3                | 2               | 6               | 0                       |
| 5          | 45              | 4                | NA              | NA              | 0                       |
| 6          | 37              | NA               | 3               | 5               | 0                       |
| 7          | 4               | 0                | 10              | NA              | 1                       |
| 8          | 49              | NA               | 10              | NA              | 0                       |
| 9          | 53              | NA               | 2               | 7               | 0                       |
| 10         | 56              | NA               | 3               | 8               | 0                       |
| 11         | 56              | NA               | 1               | 3               | 0                       |
| 12         | 53              | NA               | 2               | 5               | 0                       |
| 13         | 51              | NA               | 11              | 14              | 0                       |
| 14         | 24              | NA               | 7               | 14              | 0                       |
| 15         | 24              | 2                | NA              | NA              | 1                       |
| 16         | 63              | 4                | NA              | NA              | 1                       |
| 17         | 41              | NA               | 16              | NA              | 0                       |
| 18         | 23              | NA               | NA              | NA              | 1                       |
| 19         | 30              | NA               | 2               | 6               | 0                       |
| 20         | 46              | NA               | 3               | 5               | 0                       |
| 21         | 25              | NA               | NA              | NA              | 0                       |
| 22         | 35              | NA               | 10              | 12              | 0                       |
| 23         | 44              | NA               | 4               | 6               | 0                       |
| 24         | 47              | NA               | NA              | NA              | 0                       |

NA, not applicable.

doi:10.1371/journal.pone.0054941.t004

Table 4. Platelet recovery parameters after infusion of ex vivo-generated cells.
33% (range, 8%–77%). The dose of infused MPs for individual patients is summarized in Table 2.

**MP Infusion Toxicity Profile**

The infusion toxicity profile is summarized in Table 3. Severe adverse events associated with infusion of cultured cord blood-derived MPs were not observed. Two patients experienced fever (<38°C), four patients exhibited increased transaminases, one patient experienced increased jaundice (jaundice was present prior to infusion of MPs), and one patient experienced vomiting. All conditions were resolved with standard clinical management. With regard to four patients with elevated transaminases, we recorded the transaminase changes before and after the MP infusion. The results showed that all four patients experienced increased transaminits prior to infusion of MPs. (Figure S3) In the present clinical trial, we did not carry out the ABO blood group and HLA matching. However, after one year follow-up acute and chronic GVHD had not been observed among patients who received MPs infusion. The ABO blood group and HLA typing data of patients and paired cord blood were shown in Table S1.

**Clinical Reactions**

The median dose of infused MPs was 14.8×10⁶ MNCs/kg body weight (range, 3.2×10⁶–107.2×10⁶), and 5.45×10⁶ CD41⁺ cells/kg body weight (range, 0.3×10⁶–29.9×10⁶). Platelet recovery occurred in 17 patients with a median platelet recovery >60×10⁹/L on day 3 (median, 1 to 16 days) and in 13 patients with a median platelet recovery >100×10⁹/L on day 6 (median, 3 to 14 days). However, 5 patients received transfusion of one unit of platelets after infusion of MPs. In the absence of platelet transfusion, platelet recovery was prompt in 12 patients with a median platelet recovery >60×10⁹/L on day 3 (median, 1 to 11 days), and 11 patients with a median platelet recovery >100×10⁹/L on day 6 (median, 3 to 14 days). The summary of platelet recovery after infusion of MPs is shown in Table 4. However, it was difficult to determine whether there is any benefit to the administration of MPs after chemotherapy without appropriate controls. And definitive results will require the completion of a randomized phase 2 clinical trial.

**Discussion**

To our knowledge, this is the first report of the use of ex vivo-expanded cord blood-derived MPs in humans. We investigated the feasibility of in vitro expansion and transplantation of cord blood-derived MPs in 24 patients with advanced hematological malignancy. Administration of ex vivo-generated cell numbers up to a median of 5.45×10⁶/kg body weight was performed, with no adverse effects. Administration of cord blood-derived MPs appears to be safe and feasible for treatment of thrombocytopenia after chemotherapy.

The additional transplantation of ex vivo-generated cell populations containing up to a median of 14.8×10⁶ MNCs/kg (range, 3.2×10⁶–107.2×10⁶), and a median of 5.45×10⁶ CD41⁺ cells/kg (range, 0.3×10⁶–29.9×10⁶), is comparable to the number of additionally transplanted megakaryocytic in previous studies. [8,9] Our present study showed that there were no significant detriment to the administration of dose escalated MP. Now, many studies try to improve the efficiency of MP differentiation and expansion from stem cells. [14,15,16] The most recent studies also show that platelets can be efficiently produced from pluripotent stem cell in vitro. [17–20] All of these studies indicate promise for in vitro-produced platelet substitutes from stem cells. Our study hadn’t showed definitive efficacy of MP infusion on thrombocytopenia after chemotherapy. Other similar clinical studies have used autologous MPs or megakaryocyte infusion; however, these studies also lacked a control group, and thus cannot demonstrate the exact effect of infusion of ex-vivo-expanded studies. [2,3,8,9] Platelet recovery after chemotherapy can be influenced by patient condition, different chemotherapy regimens, and dosage and opportunity of infusion. Therefore, the efficacy of infusion of cord blood-derived MPs needs to be verified by larger phase 2 clinical trials.

There are limits in our present study. The efficiency of in vitro expansion should be improved, and platelet recovery effects need to be further explored by phase 2 study. In our study, patients had advanced hematological malignancy, and repeated chemotherapy can result in damage to the hematopoietic microenvironment, possibly influencing the effects of MP infusion.

In conclusion, this study demonstrates the safety of ex vivo-expanded MPs from CB infused after chemotherapy in patients with hematological malignancy. Our study also demonstrated the feasibility of manufacturing 3×10⁶ MPs from cord blood units to provide a cell dosage of 3.75×10⁶ cells/kg for an 80-kg recipient. However, definitive efficacy will require the completion of a randomized phase 2 clinical trial.

**Supporting Information**

Figure S1 Characterization of megakaryocytic progenitors from cord blood mononuclear cells. (A) Cell morphology of different culture time by microscope observation. Scale bars: 100 μm. Surface marker expression of CD3 (B), CD14 (C), CD19 (D), CD41 (E), CD56 (F), and CD61 (G) in expanded CB population during 14 days of culture. (H) CFU-Mk expansions after 14 days of culture. Data are shown as mean ± SD from three experiments. (l) Typical morphology of mature megakaryocytes on day 14 culture was shown. Scale bars: 50 μm. (TIF)

Figure S2 FACS plots showed the cell size and co-staining of CD41⁺ cells at day 14 culture. (A) and (B) showed the results of isotype IgG. (C) and (D) showed the results of CD41 expression. (TIF)

Figure S3 Transaminase changes of four patients before and after MPs infusion. (A) Data of patient 1. The chemotherapy time is 2009/4/7, and the MPs infusion time is 2009/4/14. (B) Data of patient 2. The chemotherapy time is 2009/5/5, and the MPs infusion time is 2009/5/19. (C) Data of patient 7. The chemotherapy time is 2009/7/30, and the MPs infusion time is 2009/8/7. (D) Data of patient 20. The chemotherapy time is 2010/3/12, and the MPs infusion time is 2010/3/23. All the four patients had different degrees of elevated transaminases before MP treatment. Dashed lines shows the normal value of ALT and AST. ALT: alanine transaminase, AST: aspartate aminotransferase. (TIF)

Table S1 ABO blood group and HLA typing data of patients and paired cord blood. (DOC)

Protocol S1 (DOC)

Protocol S2 (DOC)
Author Contributions
Conceived and designed the experiments: JFX HHZ DQL XN XTP. Performed the experiments: JFX XN LC YL. Analyzed the data: YHL XYX YFW WY. Wrote the paper: JFX HHZ JZ XTP. Patient enrollment: HHZ WZ WS. Quality control of cord blood: KYL XX XFW. Clinical study design: JFX HHZ DQL FY JZ XJH XTP.

References
1. Reems J-A, Pineault N, Sun S (2010) In Vitro Megakaryocyte Production and Platelet Biogenesis: State of the Art Transfusion Medicine Reviews 24: 33–43.
2. Decaudin D, Vantelon JM, Bourhis JH, Farace F, Bonnet ML, et al. (2004) Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma Bone Marrow Transplant 34: 1089–1093.
3. Chen TW, Hwang SM, Chiu IM, Hsu SC, Huieh TB, et al. (2009) Characterization and transplantation of induced megakaryocytes from hematopoietic stem cells for rapid platelet recovery by a two-step serum-free procedure Exp Hematol 37: 1330–1339.
4. Matsunaga T, Tanaka I, Kobune M, Kascano Y, Tanaka M, et al. (2006) Ex Vivo Large-Scale Generation of Human Platelets from Cord Blood CD34+ Cells STEM CELLS 24: 2077–2087.
5. Kishore V, Elason JF, Matthew HW (2011) Covalently immobilized glycosaminoglycans enhance megakaryocyte progenitor expansion and platelet release J Biomed Mater Res A 96: 682–692.
6. Noroozi Aghideh A, Khazaei M, Abolghasemi H, Gharrebaghi A (2010) Platelet growth factors suppress ex vivo expansion and enhance differentiation of umbilical cord blood CD34+ stem cells to megakaryocyte progenitor cells Growth Factors 28: 409–416.
7. Bruyn CD, Delforge A, Marriot P, Bron D (2005) Ex Vivo Expansion of Megakaryocyte Progenitor Cells: Cord Blood Versus Mobilized Peripheral Blood Stem Cells and Development 14: 413–424.
8. Bertolini F, Battaglia M, Pedrazzoli P, Antonio Da Prada G, Lanza A, et al. (1997) Megakaryocytic Progenitors Can Be Generated Ex Vivo and Safely Administered to Autologous Peripheral Blood Progenitor Cell Transplant Recipients Blood 89: 2679–2688.
9. Scheding S, Bergmann M, Rathke G, Vogel W, Brugger W, et al. (2004) Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy Haematologica 89: 630–631.
10. Barker JN, Wagner JE (2002) Umbilical cord blood transplantation: current state of the art Ciurr Opin Oncol 14: 160–164.
11. Barker JN, Wagner JE (2003) Umbilical-cord blood transplantation for the treatment of cancer Nat Rev Cancer 3: 526–532.
12. Reiffers J, Caillot C, Dazey B, Attal M, Caraux J, et al. (1999) Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells The Lancet 354: 1092–1093.
13. McNeice I, Jones R, Bearman SI, Cagnoni P, Nieto Y, et al. (2000) Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer Blood 96: 3001–3007.
14. Pineault N, Cortin V, Boyer L, Garnier A, Robert A, et al. (2011) Individual and synergistic cytokine effects controlling the expansion of cord blood CD34+ cells and megakaryocyte progenitors in culture Cytotherapy 13: 467–480.
15. Mercher T, Cornego MG, Sears C, Kindler T, Moore SA, et al. (2008) Notch Signaling Specifies Megakaryocyte Development from Hematopoietic Stem Cells Cell Stem Cell 3: 314–326.
16. Poitou-Chassac S, Six E, Cachian C, Lavergne M, Villeval J-L, et al. (2010) Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation Blood 116: 5670–5678.
17. Takayama N, Nishimura S, Nakamura S, Shimizu T, Ohnishi R, et al. (2010) Transient activation of c-MYC expression is critical for efficient platelet generation from human induced pluripotent stem cells The Journal of Experimental Medicine 207: 2817–2830.
18. Lu SJ, Li F, Yin H, Feng Q, Kimbrel EA, et al. (2011) Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice Cell Res 21: 530–545.
19. Gekas C, Graf T (2010) Induced pluripotent stem cell-derived human platelets: one step closer to the clinic The Journal of Experimental Medicine 207: 2781–2794.
20. Takayama N, Nishikii H, Usui J, Tsukui H, Sawaguchi A, et al. (2008) Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors Blood 111: 5298–5306.